DDInter1812 DDInter808
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. It is an anticoagulant and considered an antithrombotic. Tinzaparin must be given either subcutaneously or parenterally. LMWHs are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Garlic allergenic extract is used in allergenic testing.
Tinzaparin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Tinzaparin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Tinzaparin {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Tinzaparin {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Tinzaparin may cause a minor interaction that can limit clinical effects when taken with Chamomile
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Tinzaparin may lead to a major life threatening interaction when taken with Abciximab
Tinzaparin may lead to a major life threatening interaction when taken with Acalabrutinib